Lactobacillus rhamnosus GG

Lactobacillus rhamnosus GG (LGG) is the most clinically studied probiotic strain in the world, with over 1,000 peer-reviewed publications covering pediatric diarrhea, atopic eczema prevention, antibiotic-associated diarrhea, and respiratory health.

Supplied as a freeze-dried powder with viability between 100 and 500 billion CFU per gram at release. Demonstrated tolerance to gastric acid and bile salts, with strong adhesion to intestinal mucus via fimbrial proteins SpaCBA, supporting transient colonization of the human gut.

Off-white to light cream free-flowing powder with a clean fermented note. Particle size suitable for capsule filling, stick-pack sachets, and incorporation into chewable formats.

We supply food-grade and pharmaceutical-grade Lactobacillus rhamnosus GG from manufacturers in China holding ISO 22000, FSSC 22000, Halal, Kosher, and other certifications relevant to probiotic strain production.

Common market grades include 100, 200, and 500 billion CFU per gram freeze-dried powders, microencapsulated versions for acid and bile protection in beverage formats, and stabilized blends designed for room-temperature shelf life in finished capsule products. Bulk and reduced-MOQ shipments with batch-level COA covering viable count, strain identity, moisture, heavy metals, and full pathogen panel.

Lactobacillus rhamnosus GG was isolated from the gut of a healthy human adult in 1983 by Sherwood Gorbach and Barry Goldin at Tufts University and deposited at ATCC under accession number 53103. The GG designation reflects the initials of its discoverers.

Industrial production uses proprietary semi-defined media, high-cell-density anaerobic fermentation, centrifugal recovery, cryoprotectant blending, and lyophilization. Strain identity is verified by pulsed-field gel electrophoresis and whole-genome sequencing at each production cycle, and the SpaCBA pilus gene cluster is confirmed as a quality marker.

Regulatory positioning includes GRAS notification GRN 231 with the FDA in the United States, Qualified Presumption of Safety listing in the European Union, and inclusion in pediatric clinical guidelines published by the European Society for Pediatric Gastroenterology, Hepatology and Nutrition.

Meta-analyses confirm efficacy for shortening the duration of acute infectious diarrhea in children and reducing the incidence of antibiotic-associated diarrhea across age groups. Evidence for atopic dermatitis prevention in at-risk infants and for respiratory infection reduction in childcare settings has also been reviewed favorably.

The strain commands a price premium reflecting its clinical pedigree and is positioned as a flagship in premium probiotic capsule, sachet, and pediatric product lines worldwide.

• Pediatric probiotic drops and sachets for acute gastroenteritis and rotavirus management
• Capsules and tablets for adult digestive health and IBS support
• Functional yogurt and probiotic dairy drinks
• Infant formula fortification in markets where strain is approved
• Atopic eczema and allergy-prevention infant supplements
• Travelers diarrhea and antibiotic-recovery formulations
• Immune support and respiratory health products
• Women's health and urogenital microbiota supplements
• Premium dairy alternatives and plant-based probiotic beverages